Superior vena cava syndrome is a rare complication of transvenous pacemaker implantation (occurring in 0.4% of patients) that can be effectively managed with anticoagulation.
Answers are grounded in this paper and cite their sources.
Rare SVC syndrome after pacemaker implantation may respond to anticoagulation; leaves open need for larger prospective studies on incidence and prevention.
Superior vena cava syndrome developed in 4 of 1,000 patients in whom a transvenous pacemaker had been implanted. In all cases, endocardial leads were inserted through the cephalic vein and positioned at the apex of the right ventricle. The classical signs and symptoms of superior vena cava hypertension were observed from two weeks to one year after implantation, and the diagnosis was confirmed by cavography. Symptoms resolved following heparin therapy and long-term anticoagulation.
No takes yet. Share an insight, caveat, or question.
Chamorro et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: